KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $791.0 million.

  • Emergent BioSolutions' Non-Current Assets fell 17.43% to $674.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $674.1 million, marking a year-over-year decrease of 17.43%. This contributed to the annual value of $791.0 million for FY2024, which is 30.84% down from last year.
  • Per Emergent BioSolutions' latest filing, its Non-Current Assets stood at $791.0 million for FY2024, which was down 30.84% from $1.1 billion recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Assets peaked at $2.0 billion during FY2022, and registered a low of $791.0 million during FY2024.
  • Its 3-year average for Non-Current Assets is $1.3 billion, with a median of $1.1 billion in 2023.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Assets climbed by 15.88% in 2022, and later tumbled by 41.53% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Assets (Yearly) stood at $1.7 billion in 2020, then increased by 0.03% to $1.7 billion in 2021, then rose by 15.88% to $2.0 billion in 2022, then crashed by 41.53% to $1.1 billion in 2023, then slumped by 30.84% to $791.0 million in 2024.